LENZ Therapeutics (LENZ) Accumulated Expenses (2020 - 2026)
LENZ Therapeutics (LENZ) posted quarterly Accumulated Expenses of $14.9 million for Q1 2026, up 203.12% year-over-year from $4.9 million in Q1 2025, and down 12.59% quarter-over-quarter from $17.0 million in Q4 2025.
LENZ Therapeutics (LENZ) Accumulated Expenses (2020 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Accumulated Expenses for 7 consecutive years, with $14.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses rose 203.12% year-over-year to $14.9 million; the TTM figure through Mar 2026 stood at $14.9 million (up 203.12% YoY), while the FY2025 annual figure was $17.0 million, up 176.79% from the prior year.
- Accumulated Expenses declined to $14.9 million in Q1 2026 per LENZ's latest filing, from $17.0 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $17.0 million in Q4 2025 and bottomed at $1.0 million in Q1 2022.
- Historically, Accumulated Expenses has averaged $6.9 million across 5 years, with a median of $4.9 million in 2024.
- Annual changes were most pronounced in 2023 — Accumulated Expenses soared 615.25% — and 2025, when it sank 58.25%.
- LENZ Therapeutics' Accumulated Expenses stood at $1.9 million in 2022, then jumped by 584.29% to $12.8 million in 2023, then plunged by 51.97% to $6.1 million in 2024, then surged by 176.79% to $17.0 million in 2025, then declined by 12.59% to $14.9 million in 2026.
- Business Quant data shows LENZ's Accumulated Expenses at $14.9 million in Q1 2026, $17.0 million in Q4 2025, and $12.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | LENZ Therapeutics | 147.30 Mn | 147.30 Mn | 5.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.78 Mn |
| Mar 31, 2026 | 14.88 Mn |
| Dec 31, 2025 | 17.02 Mn |
| Sep 30, 2025 | 11.99 Mn |
| Jun 30, 2025 | 7.54 Mn |
| Mar 31, 2025 | 4.91 Mn |
| Dec 31, 2024 | 6.15 Mn |
| Sep 30, 2024 | 4.95 Mn |
| Jun 30, 2024 | 4.18 Mn |
| Mar 31, 2024 | 11.76 Mn |
| Dec 31, 2023 | 12.80 Mn |
| Sep 30, 2023 | 3.42 Mn |
| Jun 30, 2023 | 3.79 Mn |
| Mar 31, 2023 | 7.32 Mn |
| Dec 31, 2022 | 1.87 Mn |
| Sep 30, 2022 | 1.30 Mn |
| Jun 30, 2022 | 2.18 Mn |
| Mar 31, 2022 | 1.02 Mn |
| Dec 31, 2021 | 886,000.00 |
| Sep 30, 2021 | 300,000.00 |